针对肺状细胞癌的NSD抑制剂的设计,合成和抗瘤活性
Siyu Xiu1, Zhenyu Jia1, Zhiqi Wang1
1State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
European journal of medicinal chemistry
|February 26, 2025
概括
一种新型化合物A8有效抑制NSD3,这是肺状细胞癌 (LUSC) 的关键驱动因素. 这种向治疗在临床前模型中显示出强大的抗瘤作用,毒性最小,为LUSC提供了有前途的新疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- 肺状细胞癌 (LUSC) 是一种具有有限向治疗的侵袭性癌症.
- NSD3已成为LUSC病变发生的关键分子驱动因素.
- 准NSD3为LUSC提供了一个新的治疗策略.
研究的目的:
- 设计,合成和评估新型NSD3抑制剂用于LUSC治疗.
- 确定具有治疗潜力的强效和选择性NSD3抑制剂.
- 研究化合物的作用机制和临床前疗效.
主要方法:
- 合理的药物设计和NSD3抑制剂的化学合成.
- 在体外评估对NSD3和LUSC细胞系的抑制活性 (例如,NCI-H1703).
- 细胞热转移测试 (CETSA) 来确认目标接触.
- 使用异种移植小鼠模型进行体内疗效研究 (例如,NCI-H520).
- 药理动力学和毒性评估.
主要成果:
- 化合物A8在NCI-H1703细胞中显示出强大的NSD3抑制,IC50为0.355μM.
- A8显示有选择性的毒性,对非癌症HEK293T细胞的影响减少.
- CETSA证实A8与NSD3结合并稳定NSD3. CETSA证实A8与NSD3结合并稳定NSD3.
- 机理学研究表明,A8诱导了亡,并表现出剂量依赖的抗瘤作用.
- 在体内,A8表现出良好的药理动力学和抑制瘤生长,没有任何不良影响.
结论:
- 化合物A8是一种非常有前途的NSD3抑制剂用于LUSC治疗.
- 用A8化合物准NSD3为LUSC治疗提供了一个可行的策略.
- A8需要对LUSC患者进行进一步的临床研究.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.5K
05:11Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
Published on: May 10, 2024
875
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...